GSK ‘unequivocally’ committed to London listing, boss says June 21, 2024 Pharmaceuticals giant GSK has said it is "unequivocally” committed to its London listing in a soothing sign for the City after a flood of exits from the market this year.
FTSE 100 pharma giant GSK kicks off Zantac appeal as company seeks to limit damages June 11, 2024 GSK has launched an appeal against the Delaware Superior Court's recent so-called Daubert ruling.
GSK: Good news for pharma giant as approval granted to expand vaccine use June 10, 2024 The FDA has expanded its approval of a GSK vaccine that prevents respiratory syncytial virus (RSV) to affect younger adults, in a move the company hopes will prevent thousands of hospitalisations each year.
GSK shares drag the FTSE 100 as company faces muli-billion pound bill after Zantac trial ruling June 3, 2024 GSK has hit back against a US ruling that found it could be sued over the potential cancer-causing properties of its heartburn drug Zantac.
GSK: How much could the Zantac lawsuits cost? June 3, 2024 Last month, Shore Capital analysts estimated that up to $30bn (£24bn) for litigation was already priced into GSK’s shares.
GSK raises £1.25bn as it offloads final stake in Haleon May 17, 2024 The move separates the companies after a carve-up twoo years ago that saw GSK spin off and float its consumer arm as Haleon, amid fears the division was weighing on the growth of its dedicated healthcare business.
Haleon posts healthy first quarter update after UK job cuts May 1, 2024 Revenue at Haleon was up in the first quarter despite its announcement yesterday that it would cut over 400 jobs in the UK, as the consumer healthcare firm posted a quarterly update in line with expectations.
GSK raises 2024 guidance after strong vaccine sales May 1, 2024 In its first quarter, British company GSK said sales rose 10 per cent to £7.4bn but total operating profit fell 18 per cent to £1.49bn.
US regulator accepts GSK’s application to expand treatment of cancer drug April 24, 2024 The treatment, Jemperli, will now be classed as being able to help all adult patients with primary advanced or recurrent endometrial cancer. It is used alongside chemotherapy.
Covid-19 anniversary: How have GSK and Astrazeneca fared since? March 23, 2024 The Covid-19 pandemic also ignited interest in the pharmaceutical sector. Even before the UK went into lockdown, the sector was looking for ways to fight the virus.